The BASALIT multicenter trial: Gly m 4 quantification for consistency control of challenge meal batches and toward Gly m 4 threshold data

ConclusionThe novel Gly m 4 specific ELISA proved consistency of challenge meal batches over a 56‐month study period. With an average of 178 μg/g Gly m 4 in SPI, Gly m 4 lowest observed adverse effect level can be calculated once clinical lowest observed adverse effect level data based on SPI are available. Hence, sensitivity of patients can be correlated to the relevant allergen content instead of total protein of the allergenic source.

For soy food challenge of patients with birch‐associated and Gly m 4 allergen mediated soy allergy, consistently stable Gly m 4 levels were required in standardized challenge meals. A novel Gly m 4 specific ELISA proved allergen consistency in challenge meals over a 56‐month study period and allows determining lowest observed effect levels related to Gly m 4 instead of total protein.

Source: Nahrung / Food - December 4, 2016 Category: Nutrition Authors: Thomas Holzhauser, Annegret Franke, Regina Treudler, Anett Schmiedeknecht, Stefanie Randow, Wolf ‐Meinhard Becker, Jonas Lidholm, Stefan Vieths, Jan‐Christoph Simon Tags: Research Article Source Type: research